Novo Nordisk's Buyback Hits DKK 12.1 Billion While Regulators Hold the Real Verdict
Published on 11/18/2026 at 03:41 | Editorial boerse-global.deNovo Nordisk has now repurchased DKK 12.1 billion of its own shares since launching its buyback programme on 4 February, including roughly DKK 310 million of B-shares in the past week alone. The figure is concrete, settled and already reflected in the capital structure. What it cannot do is answer the question that will actually set the stock's direction: whether a pipeline of clinical wins converts into regulatory approvals — and then into revenue.
The shares slipped 2.1% on Tuesday but remain up 8.0% over 30 days, a spread that captures the tension investors are wrestling with. On one side sits a capital-return programme running on schedule. On the other, a set of filings and pending decisions whose outcomes are anything but assured.
A guidance band that still bends negative
The benchmark for the business itself came on 4 November, when Novo Nordisk raised its full-year outlook. Adjusted sales and operating profit are now each expected to land between -2% and +2% at constant exchange rates. The upgrade is a positive signal, yet both ranges still permit contraction. Anyone betting on an operational turnaround has to separate improved expectations from growth that is already locked in.
That distinction matters because the direction of adjusted operating profit — not any single weight-loss result from a trial — is the variable that will decide the investment case. The raised forecast spans both shrinkage and expansion, and those two outcomes are economically very different. The sequence of checks is straightforward: first Novo Nordisk must show it can meet the improved expectations; only then can anyone judge whether clinical progress justifies assuming growth beyond them. A guidance hike on its own settles nothing.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
CagriSema is the next hard date
The nearest fixed milestone concerns CagriSema. Novo Nordisk expects a US approval decision on the submitted 2.4 mg/2.4 mg dose in the fourth quarter of 2026, leaving the outcome open.
Supporting that case are supplementary analyses of the Phase 3 REDEFINE 1 trial, presented on Sunday. Among participants treated with CagriSema, 67.8% were classed as early responders — reaching at least 5% weight loss by week 8 — and that group went on to average a 25.4% reduction in body weight after 68 weeks. The caveat is built in: the finding describes early responders specifically and should not be extrapolated wholesale to everyone treated. As extra colour on how well the drug works, though, it reinforces the bull case.
A second regulatory track opened on Friday, when Novo Nordisk filed Etavopivat with both the FDA and the EMA for sickle cell disease in adolescents and adults aged twelve and over. Decisions are anticipated in 2027. Should those procedures go well, the company would be able to point to regulatory progress alongside its ongoing buybacks — meaning the optimistic scenario does not rest on weight-loss data alone.
Semaglutide's paediatric data add a further layer
Fresh results published yesterday in the New England Journal of Medicine from the Phase 3 STEP Young trial offer another medical anchor. In children with obesity, the estimated mean change in body mass index at 68 weeks was -17.4% on semaglutide versus +2.2% on placebo. The company also released further semaglutide findings in children with obesity alongside its CagriSema work.
These results may strengthen the clinical argument for semaglutide in the population studied. A revenue effect is not established by them, and results from one age group cannot be read as a general proof of efficacy in others. In the favourable scenario, further regulatory and commercial steps would gradually complement the medical data.
Safety warnings and open files temper the confidence
Weighing against that are tangible risks. On 10 November the FDA demanded new safety warnings for GLP-1 weight-loss medicines, a category that includes Novo Nordisk's Wegovy and Ozempic, over a possible risk of a rare eye condition. A possible risk is not proof that the condition occurs in every patient treated, but regulator-mandated warnings belong in any assessment of the drugs. A view built purely on efficacy data would be too narrow.
The pending applications demand restraint too. Filing Etavopivat is a procedural step, not a permission; the expected CagriSema decision is likewise still open. In the unfavourable scenario, disappointing verdicts could cap hopes for additional treatment options. Buybacks already executed would not be reversed — but neither would they substitute for regulatory progress that failed to arrive.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Commercial execution is the bridge
One planned step sits between approval and revenue: the first European launches of FREHEMGO, slated for next year. The European Commission granted marketing authorisation on Friday for the prevention or reduction of bleeding episodes in haemophilia A. The commercial start remains a scheduled step rather than a realised one.
The risk for investors is chiefly one of conflating different grades of evidence. A trial result is not an approval, an application is not a authorisation, and a planned launch is not booked revenue. The more an investment thesis leans on future progress, the more those distinctions matter. Even the negative scenario needs no clinical failure: it would be enough for convincing trial data to translate into commercial impact too slowly while the business tracks at the bottom of its guidance range. The raised band offers no protection against another decline.
What the next verdict will reweight
As long as approval prospects hold, the buybacks can be filed as a completed piece of corporate development sitting alongside the open drug files. A negative call on a major decision would force the optimistic case to be drawn tighter. The next concrete catalyst is the expected US ruling on CagriSema in the fourth quarter of 2026, with the Etavopivat procedures and their 2027 decisions further out.
What counts, then, is less the steady drumbeat of announcements than the status of each one: buybacks done, applications filed, approvals outstanding. Only the coming decisions will show how far the clinical progress carries once it reaches the regulator.
Ad
Novo Nordisk Stock: New Analysis - 18 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
